2023
DOI: 10.3390/children10091430
|View full text |Cite
|
Sign up to set email alerts
|

The Current Role of the sFlt-1/PlGF Ratio and the Uterine–Umbilical–Cerebral Doppler Ultrasound in Predicting and Monitoring Hypertensive Disorders of Pregnancy: An Update with a Review of the Literature

Cristian Nicolae Chirilă,
Claudiu Mărginean,
Paula Maria Chirilă
et al.

Abstract: Regarding the hypertensive disorders of pregnancy, pre-eclampsia (PE) remains one of the leading causes of severe and life-threatening maternal and fetal complications. Screening of early-onset PE (<34 weeks of pregnancy), as well as late-onset PE (≥34 weeks), shows poor performance if based solely on clinical features. In recent years, biochemical markers from maternal blood—the pro-angiogenic protein placental growth factor (PlGF) and the antiangiogenic protein soluble FMS-like tyrosine kinase 1 (sFlt-1)—… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 64 publications
0
3
0
Order By: Relevance
“…There was also a trend noted toward more rapid diagnosis of preeclampsia in the research arm that used sFlt-1 and PlGF ratios, but this trend was statistically not significant [68]. A 2023 review reported that measurement of sFlt-1/PlGF ratios can differentiate between mild and severe forms of preeclampsia as well as between gestational hypertension and preeclampsia, with higher ratios associated with more severe disease [69]. The sFlt-1/PlGF ratio has also been shown to have similar progression patterns in preeclampsia and a preeclampsia-associated syndrome involving hemolysis, elevated liver enzymes, and a low platelet count (HELLP syndrome) [70,71].…”
Section: Serum Markersmentioning
confidence: 99%
See 1 more Smart Citation
“…There was also a trend noted toward more rapid diagnosis of preeclampsia in the research arm that used sFlt-1 and PlGF ratios, but this trend was statistically not significant [68]. A 2023 review reported that measurement of sFlt-1/PlGF ratios can differentiate between mild and severe forms of preeclampsia as well as between gestational hypertension and preeclampsia, with higher ratios associated with more severe disease [69]. The sFlt-1/PlGF ratio has also been shown to have similar progression patterns in preeclampsia and a preeclampsia-associated syndrome involving hemolysis, elevated liver enzymes, and a low platelet count (HELLP syndrome) [70,71].…”
Section: Serum Markersmentioning
confidence: 99%
“…As per their proposed guidelines, a sFlt-1/PlGF ratio > 85 would signify early-onset preeclampsia and a ratio of >110 would indicate late-onset preeclampsia [73]. Recent studies demonstrate that an sFlt-1/PlGF ratio of 38 or lower could be used to predict the short-term absence of preeclampsia and that the sFlt-1/PlGF ratio is also effective at predicting preterm delivery in both early-onset and late-onset preeclampsia [69,74]. More research is needed regarding the trends and utility of using these angiogenic factors to differentiate between early-onset versus late-onset preeclampsia.…”
Section: Serum Markersmentioning
confidence: 99%
“…However, as preeclampsia represents one of the major causes of serious and sometimes life-threatening maternal and fetal complications, developing more accurate prediction models of preeclampsia as early in pregnancy as possible represents a matter of high priority. Even apparently mild forms of preeclampsia can deteriorate rapidly and without warning signs [3,8]. In this regard, plenty of recent studies have focused on the role of both biochemical markers and Doppler velocimetry parameters in the early prediction and diagnosis of preeclampsia.…”
Section: Introductionmentioning
confidence: 99%